Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

GlycoNoVi Understanding the Role of Glycans in Human Norovirus Infection: a Key to Unlock New Therapies

Coordinator
Universita Degli Studi Di Firenze, Italy
Runs
1 January 2023 to 30 June 2027
Status
Running
EU funding
€2.4m
Total cost
—
Partners
16 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101072717

What the project is doing

In the project's own words, from its summary on CORDIS.

Glycans are carbohydrate structures ubiquitously found on the surface of cells and take part in many biological processes, including cell signaling and neoplasia. Research on glycans is challenging in part due to the limited availability of biologically relevant synthetic glycans and to technical challenges in the analysis of glycan-protein interactions. Glycans also exhibit key roles in viral infections, mediating virus attachment and entry.

Human noroviruses (NoVs) are the major cause of viral gastroenteritis and foodborne illnesses causing morbidity, mortality and economic losses. NoV infections are self-limiting in healthy individuals but are associated with severe complications in immunocompromised individuals, the elderly and young children. In addition, frequently occurring new NoV genotypes and variants can cause large outbreaks and epidemics worldwide.

Very little is known about NoV infections in most non-human hosts and the close genetic similarities between some animal and human NoVs leads to the realistic hypothesis that the virus might jump the species barrier triggering pandemic variants. Importantly, no therapy is currently available to treat or prevent NoV infections. The requirement for NoVs to attach to specific glycans to infect hosts’ tissues, and cells, has been well established but the underlying mechanisms remain to be elucidated.

Going beyond the state-of-the-art, the overall aims of GlycoNoVi is training 9 researchers to address knowledge gaps on NoV glycan interactions and investigate the exciting possibility of developing synthetic glycans as antiviral strategies to treat NoV infection. These aims will be achieved bringing together 5 academic and 3 industrial leaders in glycoscience, glycovirology and NoV field and relying on a multidisciplinary and interconnected approach which is declinate in research-oriented WP1-5 and WP6-8 focused respectively on training, outreach and coordination.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di FirenzeFlorenceItalyCoordinator
InbioseZwijnaardeBelgiumParticipant
Universiteit GentGentBelgiumAssociatedpartner
Universitaet Zu LuebeckLubeckGermanyParticipant
Danmarks Tekniske UniversitetKongens LyngbyDenmarkAssociatedpartner
Glycom ASHorsholmDenmarkParticipant
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Universidad De SevillaSevillaSpainAssociatedpartner
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Universite Grenoble AlpesGrenobleFranceAssociatedpartner
React4life SpAGenovaItalyParticipant
Universita' Degli Studi Di Milano-BicoccaMilanoItalyAssociatedpartner
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Iceni Glycoscience LimitedColchesterUnited KingdomAssociatedpartner
The University of ManchesterManchesterUnited KingdomAssociatedpartner
University of East AngliaNorwichUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI